We previously developed a modified fas-1 peptide (MFK00) and peptide complexes consisting of MFK00 and RGD peptides either linked by a MMP-1 substrate (MFK24) or not as RA therapeutic agents and validated their regulatory role on βig-h3-mediated cellular functions in vitro and their therapeutic efficacy on chronic arthritis using a murine CIA model [13]. The gene discussed is TGFBI; the disease is rheumatoid arthritis.